- New help desks in Spain
and Italy offering psychological
support during COVID-19 set up
- The social initiative "Quarantine together" will provide
psychological support to families to help them in dealing with the
COVID-19 situation in both countries
- Families will receive free help and guidance in their homes
from professional psychologists via telephone or email during times
of social distancing
MILAN, BARCELONA, Spain and ASCOLI PICENO, Italy, April 3,
2020 /PRNewswire/ -- Neuraxpharm Group, a leading
European specialty pharmaceutical company focused on the treatment
of central nervous system (CNS) disorders, and present in 12
countries across Europe, today
announces the launch of the social initiative "Quarantine
Together", a psychological support platform for families in
Spain and Italy, a help desk to support families in
dealing with the COVID-19 situation in these two countries.
In some European countries, we are currently not allowed to
leave our homes. People in Italy
and Spain are most affected,
because they have been the first to have to face this new reality
as a preventative measure against the rapid spread of the
coronavirus. This has changed the dynamics in households. The
challenge to #stayathome to stop the spread of the pandemic caused
by COVID-19 is even greater for families with elderly, with
children with autism or ADHD syndrome or with members with a mental
or any other disease.
As a result of the confinement and the sudden change in the
daily routine of more vulnerable family members, it is common for
them to feel their symptoms getting worse or to suffer changes in
their emotions such as sadness, irritability or anxiety.
As a specialist in CNS, Neuraxpharm is particularly aware of the
needs of these more vulnerable individuals who need special
attention. Reflecting about Corporate Social Responsibility,
Neuraxpharm has therefore decided to launch an initiative called
"Quarantine Together". The programme consists of a free help desk
providing psychological assistance to families, and in Spain it will be offered specifically for
those families with children with Autism Spectrum Disorder
(ASD).
As a socially responsible pharmaceutical company and part of the
global community, focused on improving the quality of life of
people living with CNS disorders, Neuraxpharm aims to help the
communities in two of the European countries where the company is
present. The aim of the initiative is to provide psychological
assistance to people in need and to help them to manage their
mental health and wellbeing during the uncertain times caused by
the impact of coronavirus.
The initiative in Spain, called
"Cuarentena con TEA", runs in collaboration with the
Fundación Querer, a multidisciplinary bureau made up of experts in
children and teenage psychology that will provide medical,
therapeutic and educational guidance in Spanish. It is being
launched on April 2nd,
World Autism Awareness Day. The initiative will be promoted
through Neuraxpharm Spain's website and social media (Instagram,
Twitter and LinkedIn).
In Italy, the initiative is
called "Quarantena insieme". It will consist of a team of
professional psychologists that will provide psychological support
in Italian to families with mentally vulnerable members through a
help desk. The campaign will be launched on April 8th. The initiative will be
promoted through Neuraxpharm Italy's website and via social media
(Facebook)
Commenting on the campaign, Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm,
said: "At Neuraxpharm we are working every day to improve
the quality of life and mental wellbeing of patients affected by
disorders related to the central nervous system. Our mission as a
pharmaceutical company has more meaning than ever during these
exceptional times that we are witnessing as a result of the spread
of COVID-19. The collaborative project that we have launched in two
of the most affected countries in Europe aims to provide support to families
having vulnerable members or children with autism disorder and to
discuss solutions that will adapt to the specific needs of each
case".
Dr. Marta Fernández Gracia-Andrade, a psychologist from the
Fundación Querer added: "At the moment there are thousands
of families that are going through some very difficult times
because, besides the confinement due to COVID-19 with all the
problems that it involves, they have stopped receiving their
therapeutic and educational support and they are facing the reality
of not being able to continue with all the support from
psychologists, speech therapists or occupational and educational
therapists that they so desperately need. That is why we are glad
to join forces with Neuraxpharm on this project and help from the
expert bureau that will deal with queries from the
families."
About Neuraxpharm – the European CNS specialist
Neuraxpharm is a leading European specialty pharmaceutical
company focused on the treatment of central nervous system
disorders (CNS) with a direct presence in Germany, Spain, France, Italy, Czech
Republic, Poland,
Austria, Switzerland, Slovakia, United
Kingdom, Hungary and
Portugal. Backed by funds advised
by Apax Partners, Neuraxpharm has a unique understanding of the CNS
market built over 35 years.
With its focus on CNS, Neuraxpharm develops and commercializes
value added medicines, standard generics and Consumer Healthcare
products, e.g. probiotics and other nutraceuticals, and is
continuously striving to offer a wide range of effective, high
quality and affordable CNS treatment options in Europe.
Present with its products in more than 50 countries, Neuraxpharm
also manufactures pharmaceutical products and active pharmaceutical
ingredients in its own manufacturing sites in Spain, Lesvi and Inke.
To learn more about Neuraxpharm, please visit:
https://www.neuraxpharm.com